ACE2 and COVID-19: Although ADE has not been reported for the existing COVID-19 vaccines, a recent study has shown that antibodies against the S protein N-terminal domain enhanced the binding capacity of S protein to ACE2 and infectivity of SARS-CoV-2 (39).